Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (21)

« Back to Publications

HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics.

Mafham M. et al, (2026), Am Heart J

Fenofibrate and progression of retinopathy in adults with diabetes: the randomised placebo-controlled LENS trial.

Preiss D. et al, (2026), Health Technol Assess, 30, 1 - 70

Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.

Scotland G. et al, (2025), Diabet Med, 42

The effect of fenofibrate on progression of diabetic retinopathy according to background statin use and retinopathy grading

Silva V. et al, (2025), DIABETOLOGIA, 68, S77 - S77

Design, recruitment and baseline characteristics of the LENS trial.

LENS Collaborative Group ., (2024), Diabet Med, 41

Effect of Fenofibrate on Progression of Diabetic Retinopathy.

Preiss D. et al, (2024), NEJM Evid, 3

Diabetic Retinopathy and Quality of Life: A Systematic Review and Meta-Analysis.

Zayed MG. et al, (2024), JAMA Ophthalmol, 142, 199 - 207

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk . and RECOVERY Collaborative Group ., (2023), Lancet, 401, 1499 - 1507

Abstracts to the European Association for Diabetic Eye Complications (EAsDEC) 2023 Conference - Coimbra, Portugal, from 1st-3rd June 2023.

(2023), Eur J Ophthalmol, 33, S1 - S30

Empagliflozin in Patients with Chronic Kidney Disease.

The EMPA-KIDNEY Collaborative Group . et al, (2023), N Engl J Med, 388, 117 - 127

The Relationship Between Visual Function and Severity of Diabetic Retinopathy

Zayed MG. et al, (2023), EUROPEAN JOURNAL OF OPHTHALMOLOGY, 33, 22 - 23

Visual Function and Quality of Life in People with Diabetic Retinopathy: Insights from the Lens Trial

Preiss D. et al, (2023), EUROPEAN JOURNAL OF OPHTHALMOLOGY, 33, 24 - 24

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.

RECOVERY Collaborative Group ., (2022), Lancet, 400, 359 - 368

Care-pathways for patients presenting to emergency ambulance services with self-harm: national survey.

Zayed MG. et al, (2020), Emerg Med J, 37, 752 - 755

A man with nodules on the backs of his hands.

Zayed MG. and Bain SC., (2020), Diabet Med, 37, 1766 - 1767

Load More